Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a PET/CT study using the 18F-αvβ6-binding-peptide.The goal of this study is to evaluate this peptide in patients after infection with SARS CoV2.
The goal of the study is to to acquire 18F-αvβ6-BP PET/CT images in patients diagnosed with SARS CoV2 and to demonstrate the ability of 18F-αvβ6-BP to detect lung damage.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 18F-αvβ6-BP | Experimental | Following a 10 mCi (±20%) intravenous injection (IV) of 18F-αvβ6-BP, PET/CT images will be acquired at 60 minutes. Baseline blood samples will be drawn and banked. Vital sign (VS) measurements (heart rate, respiratory rate, blood pressure and temperature) monitored throughout. Region-of-interest analysis (ROI) will be performed in the lung. Each participant will undergo up to 3 18F- αvβ6-BP PET/CT scans over a 6-month timeframe. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 18F-αvβ6-BP | Drug | Subjects will be injected once per imaging session (a maximum of 3 imaging sessions) with up to 10 mCi (±20%) of 18F-αvβ6-BP as a rapid intravenous bolus (within 30 secs). |
| Measure | Description | Time Frame |
|---|---|---|
| Administration of 18F-αvβ6-BP | Completion of administration of 18F-αvβ6-BP in SARC CoV2 patients | baseline |
| Administration of 18F-αvβ6-BP | Completion of administration of 18F-αvβ6-BP in SARC CoV2 patients | 3 months |
| Administration of 18F-αvβ6-BP | Completion of administration of 18F-αvβ6-BP in SARC CoV2 patients | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Determine whether 18F-αvβ6-BP demonstrates accumulation in lung damage | Uptake of 18F-αvβ6-BP in lung damage will be measured by PET | baseline |
| Determine whether 18F-αvβ6-BP demonstrates accumulation in lung damage |
| Measure | Description | Time Frame |
|---|---|---|
| Determine whether 18F-αvβ6-BP accumulation in lung correlates to lung damage as indicated on CT. | Uptake of 18F-αvβ6-BP in lung measured by PET will be compared to lung damage as indicated on CT. | baseline |
| Determine whether 18F-αvβ6-BP accumulation in lung correlates to lung damage as indicated on CT. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of California Davis | Sacramento | California | 95817 | United States |
Not provided
| Label | URL |
|---|---|
| Learn more or sign up for the study here! | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Uptake of 18F-αvβ6-BP in lung damage will be measured by PET
| 3 months |
| Determine whether 18F-αvβ6-BP demonstrates accumulation in lung damage | Uptake of 18F-αvβ6-BP in lung damage will be measured by PET | 6 months |
Uptake of 18F-αvβ6-BP in lung measured by PET will be compared to lung damage as indicated on CT. |
| 3 months |
| Determine whether 18F-αvβ6-BP accumulation in lung correlates to lung damage as indicated on CT. | Uptake of 18F-αvβ6-BP in lung measured by PET will be compared to lung damage as indicated on CT. | 6 months |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |